SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Guilford (GLFD) - Steadily Rising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Dr. Bob who wrote (255)11/20/1998 8:13:00 PM
From: Steve  Read Replies (2) of 496
 
Yes I am ventilating some frustrations here. Thanks for listening. However, I affirm my assertion that selling the Company is foresight for the following reasons:

1) GLFD has huge gaps in its product development cycle. In fact, the Company has mentioned that an acquisition is a possibility. Big mistake. The stock will tank if they did such a move. I have expressed my view here to the Company. Product development gaps is probably the number one cause of the GLFD stock chart looking the way it does.

2) Evidently GLFD's scientific expertise has some holes. I point to AMGN who developed a new lead compound in the neuroimmunophilin ligand program. AMGN's expertise in proteins contributed to the development of a more potent candidate. Thus, some synergy merging with a big pharma that can supplement GLFD's expertise.

3) GLFD has a huge patent estate and they like to brag about it. However, in my opinion a patent is nothing more than a right to litigate. GLFD can hardly afford to pay $450/hour to patent attorneys for lengthy patent fights.

4) I believe GLFD has now deviated from its strategy regarding licensing compounds by taking Naaladase to phase II. I understand why they have to do this. However, it will eat up precious cash that should be spent on discovering compounds in their area of expertise.

Sure GLFD has some great potential but I did not buy into it thinking it was a lottery ticket. On the other hand I knew it wasn't a steady riser like a DELL. However, I do not believe people are investing in GLFD as a crap shot. There are too many other biotechs that have such characteristic. GLFD is a quality biotech that should trade above the other junk. Blockbuster drugs or stockbuster failures. We can avoid this by putting the Company up for sale.
I wonder how much real money Dr. Smith has at risk (stock purchased at .77 isn't real money in my opinion). He needs to do the right thing for all of the shareholders.

Regards,

Steve
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News